Compare CZWI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | CRBP |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 184.4M |
| IPO Year | 2006 | 2014 |
| Metric | CZWI | CRBP |
|---|---|---|
| Price | $21.38 | $7.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 13.3K | ★ 616.9K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | $116.00 |
| P/E Ratio | $51.28 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $13.15 | $6.73 |
| 52 Week High | $22.62 | $20.56 |
| Indicator | CZWI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 34.94 |
| Support Level | $20.22 | N/A |
| Resistance Level | $21.75 | $8.87 |
| Average True Range (ATR) | 0.57 | 0.97 |
| MACD | -0.01 | -0.41 |
| Stochastic Oscillator | 68.55 | 4.17 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.